Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

UW Psilocybin Pharmacokinetics Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02163707
Recruitment Status : Completed
First Posted : June 16, 2014
Last Update Posted : April 15, 2020
Information provided by (Responsible Party):
University of Wisconsin, Madison

Tracking Information
First Submitted Date  ICMJE June 3, 2014
First Posted Date  ICMJE June 16, 2014
Last Update Posted Date April 15, 2020
Study Start Date  ICMJE June 2014
Actual Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 13, 2014)
Determine the concentrations of psilocin following escalating doses of psilocybin [ Time Frame: 12 months ]
Determine the AUC of psilocin in plasma following single doses of 0.3, 0.45, and 0.6 mg/lg psilocybin, the precursor to psilocin.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 13, 2014)
  • Characterize any non-linearity in the pharmacokinetics of psilocybin and psilocin. [ Time Frame: 12 months ]
    Quantitate any non-linearity of the plasma AUC of psilocybin and its active metabolite psilocin after escalation doses of psilocybin.
  • Determine the effect of kidney function on psilocin pharmacokinetics. [ Time Frame: 12 months ]
    Use urine and plasma collections to quantitate the relative renal clearance of creatinine and psilocin to characterize the dependency of renal clearance of psilocin upon the glomerular filtration rate. Variation in renal function will arise from the range of ages in subjects; subjects are not selected or grouped based upon renal function.
  • Characterize the incidence and severity of adverse events associated with escalating doses of psilocybin in normal adults. [ Time Frame: 12 months ]
    The incidence and severity of expected and unexpected adverse events will be collected using the NCI Common Toxicity Criteria for Adverse Events (CTCAE) v4 during and in treatment follow-up.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE UW Psilocybin Pharmacokinetics Study
Official Title  ICMJE Pharmacokinetics of Psilocybin in Normal Adult Volunteers
Brief Summary Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. Psilocybin (4-phosphoroyloxy-N,N-dimethyltryptamine) is a hallucinogenic tryptamine that was first isolated from Psilocybe mushrooms in 1957. The objective of this Phase I clinical trial is to determine the pharmacokinetics of oral doses of psilocybin in normal, healthy adults. The study is performed in support of Phase II and Phase III studies of psilocybin for the treatment of refractory anxiety associated with incurable cancer, as well as other possible indications. Psilocybin is at present not an FDA-approved drug.
Detailed Description

The primary objective of this clinical trial is to determine the pharmacokinetics of an extemporaneous oral formulation of psilocybin in normal, healthy adults. This study is intended to add to the existing body of modern clinical research on psilocybin to support future multi-institutional Phase III clinical trials seeking to decrease anxiety and depression in patients with incurable cancer. The long-term goal of this research is to submit a successful new drug application for psilocybin to the FDA.

Subjects will initially take one 0.3 mg/kg (approximately 20mg/70kg) oral dose of psilocybin to initiate an eight hour chaperoned outpatient experience. After eight hours of outpatient sampling, the subject will be transported across the street to the UW Institute for Clinical and Translational Research Clinical Research Unit (ICTR CRU) for an overnight stay and additional blood and urine sampling. Pre- and post-treatment psychologic preparation and debriefing interviews will be required.

A minimum of four weeks after the first dose, the subject will receive a second oral dose of psilocybin at the higher dose of 0.45 mg/kg (approximately 30 mg/70 kg). This dosing will again take place in an attended, structured setting with timed blood and urine samples obtained both in the School of Pharmacy (0-8 hours) and in the UW Clinical Research Unit (8-24 hours). A minimum of four weeks after the second dose, the subject will receive a third oral dose of psilocybin at the highest dose of 0.6 mg/kg (approximately 40 mg/70 kg). This dose will again take place in an attended, structured setting with timed blood and urine samples obtained both in the School of Pharmacy (0-8 hours) and in the UW Clinical Research Unit (8-24 hours).

12-lead ECGs will be obtained at specified time points before and during each treatment period. Throughout the duration of drug action for each dose participants will be attended by two trained monitors, and a physician will available during the entire 24 hour treatment and sampling period.

Subjects who have been administered the first dose but decline to receive any subsequent doses will remain evaluable. At that time their active study participation will end.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE Drug: Psilocybin
Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
Study Arms  ICMJE
  • Psilocybin Dose 1
    0.3 mg/kg (approximately 20mg/70kg)
    Intervention: Drug: Psilocybin
  • Psilocybin Dose 2
    0.45 mg/kg (approximately 30 mg/70 kg)
    Intervention: Drug: Psilocybin
  • Psilocybin Dose 3
    0.6 mg/kg (approximately 40 mg/70 kg)
    Intervention: Drug: Psilocybin
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 13, 2014)
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 2015
Actual Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Aged 21 - 80 years
  • Able to read, speak, and understand spoken English
  • Self-report of at least one prior positive hallucinogen drug experience that included a meaningful altered state of consciousness. Hallucinogenic substances can include psilocybin, LSD, or other classic hallucinogens.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 based upon CRU NP or study physician physical exam, which indicates a subject is fully functioning.
  • A woman of childbearing potential must agree to practice an effective means of birth control during their participation in the clinical trial, up to and including the 90 day follow-up after their last psilocybin dose. Birth control method and written agreement to practice this method throughout the duration of the study will be documented on the Medical History Case Report Form. Effective contraception is defined as the regular use of one of the following:

    • Established use of oral, injected, or implanted hormonal methods of contraception
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS)
    • Barrier methods: Condom or Occlusive cap used with a spermicide
    • female sterilization/hysterectomy (with documentation of surgery)
    • post-menopausal (>12 months since last menses at the time of screening)
    • Male sterilization (with post-vasectomy documentation)
    • True abstinence
  • Ability and willingness to adhere to study requirements, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations.
  • Agree to refrain from using any psychoactive drugs, including alcoholic beverages and tobacco, within 24 hours of each drug administration. The exception is caffeine.
  • Participants will be required to be non-smokers.

Exclusion Criteria:

  • Estimated creatinine clearance <30 ml/min, using the Cockcroft Gault equation and actual body weight.
  • Clinically significant abnormal chemistry or hematologic laboratory results (from a screen of Complete Blood Count with Differential and Comprehensive Metabolic Panel), using the UWHC core lab reference intervals.
  • Females of childbearing potential with positive urine pregnancy at screening or the day of the first treatment.
  • Clinically significant abnormalities in physical examination.
  • Inadequately treated hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg).
  • Personal history of primary psychotic disorder (unless substance-induced or due to a medical condition), bipolar affective disorder Type I or Type II, or schizophrenia.
  • First or second-degree family history of primary psychotic disorder, bipolar affective disorder Type I, bipolar affective disorder Type II, or schizophrenia.
  • Substance abuse or dependency within the past five years.
  • Suicidal ideation or attempt within the past 30 days and/or any prior suicidal ideation/attempt that the study physician and PI feel makes the participant unsuitable for the study.
  • Urine drug test containing non-prescribed drugs of abuse (non-prescribed opioids, benzodiazepines, amphetamines, phencyclidine, cocaine) at screening and day of first treatment. Urine cannabinoid concentrations >50 ng/ml will suggest heavy marijuana use, and will be a threshold for excluding potential subjects.
  • Current use of monoamine oxidase inhibitors or dopaminergic antagonists. Any prohibited agents must have been stopped at least 5x the elimination half-life of the specific drug.
  • Subject does not have a local support person that is available during their 24 hour treatment and observation period.
  • Concurrent or recent (within 5 years) history of major depression, obsessive-compulsive disorder, panic disorder, anorexia nervosa, or bulimia nervosa.
  • Poor venous access.
  • Known acute coronary syndrome or angina.
  • Evidence of ischemic disease or ventricular arrhythmias on screening ECG.
  • Cardiac conduction defects on screening ECG.
  • Cardiac transplantation as determined by self-report during review of medical history.
  • Lactose intolerance (excipient in psilocybin capsules)
  • Type I or insulin-dependent Type II diabetes.
  • Prescription medicine requiring dosing during the 8 hours of drug action.
  • Current or recent (past 5 years) seizure disorder as determined by self-report during medical history and physical exam.
  • Chronic or frequent migraines.
  • Regular or frequent use of benzodiazepines.
  • Attention Deficit Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD).
  • Regular or frequent use of stimulants.
  • Generalized Anxiety Disorder (GAD).
  • Post-Traumatic Stress Disorder (PTSD).
  • Neuroleptic medications.
  • Any physical or psychological symptom, based on the clinical judgment of the study physician and/or psychologist , that would make a participant unsuitable for the study.
  • Any use of a medication(s), based on the clinical judgment of the study physician, that would make a participant unsuitable for the study.
  • Any finding(s), based on the screening process, that the PI feels makes the participant unsuitable for the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT02163707
Other Study ID Numbers  ICMJE 2013-0998
A561000 ( Other Identifier: UW Madison )
PHARM\PHARMACY\PHARMACY ( Other Identifier: UW Madison )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Wisconsin, Madison
Study Sponsor  ICMJE University of Wisconsin, Madison
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Paul Hutson, PharmD University of Wisconsin, School of Pharmacy
PRS Account University of Wisconsin, Madison
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP